Though the direct cancer cell-killing is not sufficient to reduce tumor growth in several cancer models [44, 63, 64], it may provide more tumor antigens for cross-presentation to initiate the tumor-immune cycle [14, 15], and/or sensitize cancer cells to other cytotoxic agents or active CD8+ T cell-mediated killing. This evidence concerns the gene CD8A and neoplasm.